Sign In
Buy IOBT
$0.0480
+0 (+0%)
At Close: Jun 22, 2026
IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analysts
04:10am, Saturday, 18'th Apr 2026
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received an average rating of "Reduce" from the five analysts that are currently covering the stock, Marketbeat reports. Two investment analysts h
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33
01:31am, Friday, 27'th Mar 2026
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received a consensus rating of "Reduce" from the five research firms that are presently covering the firm, MarketBeat reports. Two equities resear
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest
01:16am, Monday, 02'nd Mar 2026
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 4,262,939 shares, a drop of
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
10:55am, Friday, 13'th Feb 2026
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could m
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 47.2%
04:41am, Sunday, 01'st Feb 2026
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,083,79
IO Biotech Provides Corporate Update
08:05am, Friday, 30'th Jan 2026
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing n
IO Biotech Announces Exploration of Strategic Alternatives
05:30am, Wednesday, 21'st Jan 2026
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
04:05pm, Monday, 15'th Dec 2025
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free surviv
IO Biotech Announces Participation in Upcoming December Investor Conferences
10:46am, Wednesday, 26'th Nov 2025
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 19'th Nov 2025
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IO Biotech, Inc. (NASDAQ:IOBT) Receives Average Rating of “Hold” from Analysts
03:11am, Wednesday, 19'th Nov 2025
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has earned an average rating of "Hold" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
08:05am, Friday, 14'th Nov 2025
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou
IO Biotech Announces Participation in Upcoming Investor Conferences
08:30am, Wednesday, 12'th Nov 2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vac
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
02:30am, Monday, 20'th Oct 2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression
